Imagine a world where it’s never
too late for a cure.
Cure-One™ (formerly MED-C),
is a non-profit organization,
determined to advance
precision medicine by making
life-saving data readily
accessible to physicians,
researchers, insurance and
through a consortium of
healthcare’s most influential
See Press Release
Introducing the N1 Registry™
A Comprehensive Genomic-
Outcome Database to Benefit All
Cure-One has created an independent registry that connects the dots between standardized molecular testing from labs and the ongoing development of clinical outcomes for cancer patients. It’s a huge step forward.
Serves An Unmet Need – Groups such as payors, regulators, patients, providers, researchers and industry stakeholders desire a unified source for standardized, validated and granular molecular data that ties to clinical outcomes.
Is Patient Centered and IRB Approved – Patients are educated and enrolled through informed consent and have the opportunity to opt in or out at any time. The utmost care is given to protecting patient genomic data.
Is A Catalyst for Higher-Quality Care – Our N1
Registry collects high-level clinical outcomes related to standardized molecular testing and the ongoing review allows continual improvement of testing and treatments.
Accelerates the Clinical Trial Process – Through direct entry into clinical trials or development of new diagnostic and therapeutic interventions.
Is An Independent and Honest Broker – Allowing data collection, analysis, and research to be equally accessible to all healthcare participants at the lowest possible cost.
Is Led By Experts in Precision Medicine – World renowned experts in precision medicine fill key roles and bring expertise to oversee the quality and success of the N1 Registry.
The N1 Registry – How it Works
and What It Means For You:
- Reimbursed targeted therapies
- Clinical trial access
- Data for publication
- Standardized genomic testing
- Reimbursed NGS testing
- Competitive advantage
- Increased trial participation
- Ability to participate in a quality initiative
- Quicker drug-to-market
- Testing reliability and patient enrollment
- Access to consented data outcomes
- Standardized molecular diagnostic testing
- Reimbursing effective treatments and diagnostics
- Improved quality genomic and clinical data
- Increased access to information and technologies.
- Receiving true treatment alternatives based on consented patient data